No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors

Blood

Volumn 98, Issue 6, 2001, Pages 1739-1745

  Remberger, Mats ^a,b,c   Ringdén, Oolle ^a,b,c   Blau, Igor Wolfgang ^a,b,c   Ottinger, Hellmut ^a,b,c   Kremens, Bernhard ^a,b,c   Kiehl, Micheil G ^a,b,c   Aschan, Johan ^a,b,c   Beelen, Dietrich W ^a,b,c   Basara, Nadezda ^a,b,c   Kumlien, Gunilla ^a,b,c   Fauser, Axel A ^a,b,c   Runde, Volker ^a,b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Haematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROBABILITY; RELAPSE; SURVIVAL RATE; THROMBOCYTE; WHOLE BODY RADIATION;

EID: 0035885966     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1739     Document Type: Article

References (47)

1. Kessinger A, Smith D, Strandjord S. Allogeneic transplantation of blood-derived, T cell-depleted hematopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant. 1989;4:643-646.
2. Dreger P, Suttorp M, Haferlach T, Löffler H, Schmitz N, Schroyes W. Allogeneic granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood. 1993;81:1404-1407.
3. Russell NH, Hunter AE. Peripheral blood stem cells for allogeneic transplantation [editorial]. Bone Marrow Transplant. 1994;13:353-355.
4. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655-1658.
5. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659-1665.
6. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995;85:1666-1672.
7. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996;88:2794-2800.
8. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation [see comments]. Bone Marrow Transplant. 1998;21:995-1003.
9. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231-1237.
10. Blau IW, Basara N, Lentini G, et al. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. Bone Marrow Transplant. 2001;27:27-33.
11. Fauser AA, Basara N, Blau IW, Kiehl MG. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single-centre study. Bone Marrow Transplant. 2000;25(suppl 2):S27-S31.
12. Hägglund H, Ringdén O, Remberger M, et al. Faster neutrophil and platelet engraftment, but no difference in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplant. 1998;22:131-136.
13. Ringdén O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94:455-464.
14. Ringdén O, Hägglund H, Runde V, et al. Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplant. 1998;21(suppl 3):S81-S84.
15. Singhal S, Powles R, Kulkarni S, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplant. 2000;25:501-505.
16. Ringdén O, Lönnqvist B, Hägglund H, et al. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease [letter]. Bone Marrow Transplant. 1995;16:856-857.
17. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705-4709.
18. Scott MA, Gandhi MK, Jestice HK, Mahendra P, Bass G, Marcus RE. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case-controlled study. Bone Marrow Transplant. 1998;22:273-276.
19. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537-546.
20. Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation, Tissue Antigens. 1992;39:225-235.
21. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83:2723-2730.
22. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplantation. 1995;15:619-625.
23. Beelen DW, Ottinger HD, Elmaagacli A, et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood. 1997;90:4725-4735.
24. Remberger M, Svahn B-M, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:823-830.
25. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
26. Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man: a clinico-pathological study of 20 long-term Seattle patients. Am J Med. 1980;69:204-217.
27. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1996;17:583-587.
28. Ljungman P, Plotkin S. Definition, clinical severity scores and new syndromes. Scand J Infect Dis Suppl. 1995;99:87-88.
29. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
31. Breslow N, Day N, Davis W. Statistical Methods in Cancer Research. Vol. 1. The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
32. Cox D. Regression models and life-tables. J R Stat Soc (Series B). 1972;34:187-220.
33. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223-3228.
34. Bishop MR, Tarantolo SR, Geller RB, et al. A randomised, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80-85.
35. Beatty P, Hansen J, Longton G, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51:443-447.
36. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program [see comments]. N Engl J Med. 1993;328:593- 602.
37. Ringden O, Remberger M, Carlens S, et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning, including anti-T-cell antibodies. Transplantation. 1998;66:620-625.
38. Storb R, Deeg H, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
39. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol. 1985;13:1062-1067.
40. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755-761.
41. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702-3709.
42. Przepiorka D, Anderlini P, Ippoliti C, et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997;19:455-460.
43. Bensinger W, Martin P, Clift R, et al. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies. Blood. 1999;94(suppl 1):368a.
44. Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;18:921-929.
45. Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood. 1989;75:555-562.
46. Carlens S, Ringdén O, Aschan J, et al. Risk factors in bone marrow transplant recipients with leukaemia: increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant. 1989;12:84-92.
47. Gratwohl A, Hermans J, Apperly J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:813-818.